



## GAGNANTS DE LA BOURSE DR ANDREW R. BELCH POUR ENCOURAGER L'ÉDUCATION ET LA FORMATION CONTINUE DE JEUNES CHERCHEURS DANS LE DOMAINE DU MYÉLOME (EFCM)

### 2019

- **Dre Eva Laverdure** – Clinical and Prognostic Impact of Circulating Plasma Cells on Peripheral Blood Smears in Multiple Myeloma at Presentation and During Follow-up
- **Dre Hannah Cherniawsky** – The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting
- **Dre Bethany Monteith Ames** – Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with Highdose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)
- **Aline Rangel Pozzo** – The Three Dimensional (3D) Spatial Distribution of Lamin A/C in the Nuclei of Myeloma Cells

### 2022

- **Dr Jean-Sébastien Claveau** – Bortezomib Maintenance after Upfront Allogeneic Transplantation in Myeloma Patients: Less Chronic GVHD and Immunosuppression but Still No Impact on Survival
- **Dre Holly Lee** – Point Mutations in BCMA Extracellular Domain Mediate Resistance to BCMA Targeting Immune Therapies
- **Dre Alissa Visram** – The Impact of Marginalization on Treatment Receipt and Overall Survival in Newly Diagnosed Multiple Myeloma Patients in Ontario: A Population-based Cohort Study
- **Afsaneh Panahi** – Identification of Misclassified Multiple Myeloma Patient Risk Subgroups with a Novel Biological Disease Stratifier
- **Samantha Fowler** – Moving from Research Priorities to Clinical Research: Implementing the Results of a Priority Setting Partnership on Multiple Myeloma
- **Dr Guido Lancman** – Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

## 2023

- **Dr Jean-Sébastien Claveau** – Bone Marrow MRD and Immune Microenvironment in Myeloma Long-term Progression-free Survivors After Autologous or Allogeneic Hematopoietic Cell Transplantation
- **Afsaneh Panahi** – Identification of Misclassified Multiple Myeloma Patient Risk Subgroups With a Novel Biological Disease Stratifier
- **Melika Bakharzi** – Optimizing the Vk\*MYC Multiple Myeloma Model to Investigate Osteolytic Bone Lesions
- **Lorenzo Lindo** – Canadian-made Single Domain Antibody (sdAb) BCMA Car-T Cells for Multiple Myeloma
- **Dory Abelman** – Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma
- **Noémie Leblay, PhD** – A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones
- **Dre Alissa Visram** – Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-world of Treatments for Multiple Myeloma: A Population-based Cohort Study
- **Pallavi Ganguli** – Primary Care Management Pathways To Reduce Wait Times In Hematology: Monoclonal Gammopathy Of Undetermined Significance

## 2024

- **Afsaneh Panahi** – Exploiting APOBEC3B-induced Vulnerabilities for Risk-adapted Treatment in Multiple Myeloma Patients with Del(17p)
- **Melika Bakharzi** – Heterogeneity of Osteoclasts In Multiple Myeloma Revealed by Single-nucleus RNA Sequencing
- **Dory Abelman** – Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
- **Dre Rintu Sharma** – Outcomes of Relapsed/refractory Multiple Myeloma Patients Receiving Sequential Therapies After Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
- **Dr Steven Shih** – Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-eligible Patients with Multiple Myeloma

## 2025

- **Melika Bakharzi** – Molecular Insights into Multiple Myeloma Bone Disease: Single-Nucleus RNA-seq Analysis of Osteoclast Differentiation
- **Ariene Cabantog** – Defining a Novel Cytokine Combination to Optimize in vitro Culture Conditions for Primary Multiple Myeloma Cells
- **Simin Ahmadvand** – BCMA-Directed CAR-NK and BiKE Therapies Enhance NK Cell Cytotoxicity in Primary Multiple Myeloma
- **Ankita Dabla, PhD** – Nanobody-based Multifunctional Killer Engagers for Next-Gen BCMA-Directed Myeloma Therapy
- **Dre Daniela Di Francesco** – Importance of Re-induction in Patients with Transplant Eligible Multiple Myeloma Refractory to Frontline Therapy
- **Lorenzo Lindo, BSc** – A Syngeneic Mouse Model of CAR-T Cell Therapy Containing a Translatable Dual Human/Mouse Reactive sdAb Binder in Vk\*MYC Mice Reveals Clinically-relevant Microenvironment Changes
- **Ben J. Patrick, MSc** – Deciphering Genomic Correlates of Differential Treatment Response Kinetics in Multiple Myeloma
- **Dre Andrée-Anne Pelland** – Real-world Outcomes of Patients with Multiple Myeloma who Received BCMA-targeted Bispecific Antibodies in British Columbia